On April 11, 2018 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), reported its presence at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR) (Free AACR Whitepaper) that is being held April 14 – 18 in Chicago, Illinois (Press release, Actinium Pharmaceuticals, APR 11, 2018, View Source [SID1234525264]). Actinium will feature its AWE Technology Platform at AACR (Free AACR Whitepaper) including additional data from the Company’s efforts focused on creating biobetters and novel antibody radio-conjugates (ARCs). Recently, Actinium announced that it has entered into a collaborative research agreement with Astellas Pharma, Inc. that will leverage the Company’s AWE Technology Platform to conjugate and label select Astellas targeting agents with actinium-225. Actinium submitted additional data that has been accepted for poster presentation at AACR (Free AACR Whitepaper), the details of which are below: Details on the poster are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Conjugation of daratumumab with 225actinium greatly increases its antitumor activity against multiple myeloma tumors
Abstract Number: 760
Session Category: Experimental and Molecular Therapeutics
Date: Sunday, April 15, 2018, 1:00 – 5:00 PM
At time of abstract submission, the Ac-225 labelled daratumumab at an equimolar concentration demonstrated superior antitumor activity to naked daratumumab in a highly predictive DAUDI model and provided a survival benefit. Additional details will be presented during the poster session at the Annual Meeting.
To arrange a meeting with Actinium Pharmaceuticals at AARC or to learn more about Actinium’s AWE Technology Platform, please contact Keisha Thomas, Ph.D., Corporate Development at [email protected] or visit View Source
Dr. Dale Ludwig, Actinium’s Chief Scientific Officer said, "We are heading to AACR (Free AACR Whitepaper) with significant momentum around our AWE Technology program following our recently announced collaboration with Astellas and following the exciting preclinical data we published at ASH (Free ASH Whitepaper). At AACR (Free AACR Whitepaper), we will be presenting additional preclinical data further demonstrating the utility and benefits of our AWE Technology platform in enhancing the potency of anti-cancer targeting agents. Collectively, this will showcase our capabilities and we look forward to the interactions we will have with biopharmaceutical companies attending the Annual AACR (Free AACR Whitepaper) meeting."
Recently, Actinium presented data at the American Society of Hematology (ASH) (Free ASH Whitepaper) demonstrating the Company’s ability to utilize AWE Technology to dramatically enhance the potency of daratumumab, CD38 targeted therapy for patients with multiple myeloma which is marketed by Johnson & Johnson as Darzalex, by stably labeling the antibody with the isotope actinium-225. In doing so, tumor cell death in vitro was dramatically enhanced, resulting in potent and selective CD38-dependent cell killing approaching 100% in each of the lines tested.
Sandesh Seth, Actinium’s Chairman and CEO said, "We see great potential for our AWE Technology Platform and are encouraged that it has been validated by our collaboration with Astellas Pharma, Inc., a top twenty global biopharmaceutical company. Having formalized our AWE Technology Program less than 6 months ago, we are incredibly pleased with the progress we have made, the team we have built and the data we have generated. Actinium is committed to leading the field in alpha-particle therapies driven by cutting edge research and development, strong translation into clinical programs and building a robust infrastructure that can support late stage development and commercialization."
About Our Actinium Warhead Enabling Technology Platform
The Actinium Warhead Enabling (AWE) Technology Platform enables a highly potent and selective form of targeted therapy that combines the powerful alpha-emitting radioisotope actinium-225 with targeting agents, which are designed to seek out cancer cells in the body that express particular markers. Actinium-225 emits significant alpha radiation making it a potent treatment modality against targeted cancer cells while limiting damage to healthy tissues as its radiation travels extremely short distances in the body. When labeled to targeting agents, actinium-225 can be delivered directly to cancer cells where the high linear energy transfer resulting from the emission of alpha particles results in irreparable DNA double stranded breaks and ultimately cancer cell death. Even though it exhibits superior cell killing power, actinium-225, when delivered in a targeted manner, is sparing of the surrounding environment in the body due to the short path length of its alpha-particle radiation and can result in a superior safety profile. Actinium Pharmaceuticals owns or has licensed the rights to several issued and pending patents that pertain to its AWE Technology Platform including technology to manufacture Actinium-225 in a cyclotron. In addition, the Company obtains actinium-225 from various sources such as the U.S. Department of Energy at Oak Ridge National Laboratories and has developed considerable know-how, expertise and validated processes related to production of Actinium Radio-Conjugates (ARC’s), management of the supply chain and dealing with various regulatory bodies. The AWE Technology Platform can be utilized to potentially improve the cell-killing power of targeting agents such as antibodies, peptides, Fab fragments, nanobodies etc. via labeling with Actinium-225. In addition to increased efficacy, these Actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation of biobetters or improved versions of the approved agent. The Company’s Actinium Warhead Enabling (AWE) Program can be accessed by biopharmaceutical companies that are interested in creating biobetters through the utilization of the AWE Platform Technology. To learn more about the AWE Technology Platform or the AWE Program please contact Keisha Thomas, Ph.D., Corporate Development at [email protected]